A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

BACKGROUND: Hyperphosphatemia is associated with increased fibroblast growth factor 23 (FGF23), arterial calcification, and cardiovascular mortality. Effects of phosphate-lowering medication on vascular calcification and arterial stiffness in CKD remain uncertain. METHODS: To assess the effects of n...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Soc Nephrol
Autori principali: Toussaint, Nigel D., Pedagogos, Eugenia, Lioufas, Nicole M., Elder, Grahame J., Pascoe, Elaine M., Badve, Sunil V., Valks, Andrea, Block, Geoffrey A., Boudville, Neil, Cameron, James D., Campbell, Katrina L., Chen, Sylvia S.M., Faull, Randall J., Holt, Stephen G., Jackson, Dana, Jardine, Meg J., Johnson, David W., Kerr, Peter G., Lau, Kenneth K., Hooi, Lai-Seong, Narayan, Om, Perkovic, Vlado, Polkinghorne, Kevan R., Pollock, Carol A., Reidlinger, Donna, Robison, Laura, Smith, Edward R., Walker, Robert J., Wang, Angela Yee Moon, Hawley, Carmel M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2020
Soggetti:
Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7608977/
https://ncbi.nlm.nih.gov/pubmed/32917784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2020040411
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi